Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.

Uncu, DoganBayoglu, Ibrahim VedatArslan, Ulku YalcintasKucukoner, MehmetArtac, MehmetKoca, DoganOguz, Arzu2024-04-242024-04-2420140732-183X1527-7755https://doi.org/10.1200/jco.2014.32.15_suppl.e11586https://hdl.handle.net/11468/1828150th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 30-JUN 03, 2014 -- Chicago, IL[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.Conference Object3215WOS:00035861320008010.1200/jco.2014.32.15_suppl.e11586Q1